Fact CheckerSign in

NCT07410247Recruiting

MPN Childhood Registry

The Myeloproliferative Neoplasms (MPN) Childhood Registry and Biobank

Source: ClinicalTrials.gov · Last updated 1 May 2026

Brief summary (registry, in English)

Myeloproliferative neoplasms (MPNs) are caused by defects in blood cell production. This leads to an overproduction of mature cells, such as red blood cells or platelets. As a result, clinical symptoms and complications can develop. Circulatory disorders and resulting pain symptoms, such as headaches, are the most prominent. Furthermore, blood clotting disorders can occur, leading to vascular occlusions or bleeding. Over a longer period, bone marrow transformation into fibrous tissue or the development of acute leukemia can occur, resulting in even more serious complications. In the vast majority of cases, MPNs are diagnosed in older adults. These diagnoses are extremely rare in children and adolescents. Therefore, clinical and genetic characteristics, treatment options, and outcomes in pediatric patients with MPNs are insufficiently described, and only limited data are available for standardizing diagnostic and therapeutic approaches for MPNs in childhood and adolescence. Recommendations and guidelines from the adult field, which have largely been adopted and applied to children and adolescents, do not adequately address the specific needs of patients in childhood and adolescence. To gain more insights into MPN during this early, vulnerable phase of life, we have established a nationwide registry in Germany that systematically collects data from children and adolescents with MPN. The registry focuses particularly on the scientific analysis of the biological characteristics and differences of MPN in children and adolescents compared to adults.

Status (registry)
Recruiting
Study type
Observational
Enrollment
500 (estimated)
First submitted
8 Feb 2026
Start date
1 Jan 2023
Primary completion date
31 Dec 2032
Lead sponsor
University of Erlangen-Nürnberg Medical School
NCT number
NCT07410247

What you commit to

  • Study type: Observational
  • Planned participants: 500
  • From 1 Jan 2023 to the primary completion date, 31 Dec 2032
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • o Secondary polycythemia, thrombocytosis, myelofibrosis or HES with underlying reasons other than PV, ET, PMF or pHES

Who the study is looking for

  • Newly diagnosed PV, ET, PMF or pHES
  • Age \< 18 years (up to 17 years and 365 days) at the day of diagnosis
  • Patient treated in a participating center
  • Written informed consent to registry participation

Age in the registry: 0 years to 17 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany
Coordinator of this site? Confirm its status
ErlangenGermanyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.